Cronkhite–Canada syndrome

From WikiMD's WELLNESSPEDIA

(Redirected from Cronkhite-Canada syndrome)

Blausen 0432 GastroIntestinalSystem

Cronkhite–Canada syndrome (CCS) is a rare, non-inherited gastrointestinal disorder characterized by diffuse polyposis of the digestive tract, along with ectodermal abnormalities such as alopecia, skin hyperpigmentation, and onychodystrophy. The syndrome was first described by Dr. Leonard W. Cronkhite Jr. and Dr. Wilma Jeanne Canada in 1955.

Clinical Features[edit]

Patients with Cronkhite–Canada syndrome typically present with symptoms such as diarrhea, weight loss, abdominal pain, and anorexia. The polyps found in CCS are usually hamartomatous and can occur throughout the gastrointestinal tract, including the stomach, small intestine, colon, and rectum.

Pathophysiology[edit]

The exact cause of Cronkhite–Canada syndrome remains unknown. However, it is believed to involve an abnormal immune response leading to inflammation and subsequent polyp formation. The syndrome is not inherited, and no specific genetic mutations have been consistently associated with it.

Diagnosis[edit]

Diagnosis of Cronkhite–Canada syndrome is primarily based on clinical presentation and endoscopic findings. Endoscopy and colonoscopy are used to visualize the polyps, and biopsy samples are taken to rule out other conditions. Additional tests may include CT scans, MRI, and laboratory tests to assess nutritional deficiencies and inflammatory markers.

Treatment[edit]

There is no specific cure for Cronkhite–Canada syndrome. Treatment focuses on managing symptoms and nutritional support. This may include corticosteroids, immunosuppressive drugs, and nutritional supplements. In severe cases, total parenteral nutrition (TPN) may be necessary. Regular monitoring and follow-up are essential to manage complications and assess the effectiveness of treatment.

Prognosis[edit]

The prognosis for patients with Cronkhite–Canada syndrome varies. Some patients respond well to treatment and experience symptom relief, while others may have a more chronic and relapsing course. Complications such as malnutrition, sepsis, and gastrointestinal bleeding can significantly impact the prognosis.

Related Pages[edit]

Categories[edit]


Medical condition






















Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.